Evidence — BPC-157
peptide · asset evidence level: emerging
Evidence quality breakdown (linked documents)
expert_opinion: 3preclinical: 1
Linked source documents (4)
- Integrative Peptide Therapy — Clinical Reference Protocol (Demo Import) (physician_protocol · expert_opinion)
- Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model.docx (physician_protocol · expert_opinion)
- Synergistic Effects of BPC-157, KPV, Thymosin Alpha-1, GHK-Cu, and Targeted Nutritional Cofactors on Bell’s Palsy Reversal in a Facial Nerve Crush Murine Model.docx (physician_protocol · expert_opinion)
- BPC-157: Preclinical Tissue-Repair Profile (internal_protocol · preclinical)
Provider dosing references (Stage 9, source-attributed)
250-500 mcg once or twice daily — Practitioner Peptide Dosing Reference (commonly published ranges)
Dosing claims (35) · Safety claims (8)
Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.